Improved characteristics and protective efficacy in an animal model of E. coli-derived recombinant double-layered rotavirus virus-like particles

Li, Tingdong; Lin, Haijun; Zhang, Yue; Li, Min; Wang, Daning; Che, Yaojian; Zhu, Yu; Li, Shaowei; Zhang, Jun; Ge, Shengxiang; Zhao, Qinjian; Xia, Ningshao

doi:10.1016/j.vaccine.2014.01.093

Cited by 35 publications

(48 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All samples (0.5 mg/ml) were degassed and measured at a scan rate of 90 • C/h with the scan temperature from 25 • C to 90 • C. Data analysis was performed using MicroCal-enabled Origin software. The transition midpoint (T m ) was determined from the Cp-temperature curves [25].…”

Section: Differential Scanning Calorimetry (Dsc)mentioning

confidence: 99%

“…The mice with a diarrhea score of 1 and ≥2 were considered as normal and with diarrhea, respectively. And those with a diarrhea score of 3 were considered as with severe diarrhea [25].…”

Section: Animal Immunization and Virus Challengementioning

confidence: 99%

“…However, the eukaryotic expression of VLPs need simultaneous expression of several recombinant rotavirus proteins in a single cell, which poses challenges for vaccine bioprocessing and bioanalytics [24]. Recently, soluble rotavirus middle-layer capsid protein VP6 and inner-layer capsid protein VP2 were successfully expressed in Escherichia coli (E. coli) respectively in our laboratory and were assembled into homogeneous double-layered VP2/6-VLPs, which showed significant protection against rotavirus-induced diarrhea in pups when assessed using a mouse maternal antibody model [25]. However, because it is not the surface viron protein, VP6 protein elicits only the immunity inhibiting intracellular replication of rotavirus in infected intestinal cells [26], but does not induce neutralizing antibodies which prevent the rotavirus infection.…”

Section: Introductionmentioning

confidence: 99%

“…A comparative study of the soluble expression level, yield, physicochemical characteristics, immunogenicity and protective efficacy in a mouse maternal antibody model [25] was conducted. The protective efficacy of VP8-1 in a mouse model was comparable to that of the full length protein VP8*, which was significantly higher than that of VP8-2 and VP8*.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Characterization and protective efficacy in an animal model of a novel truncated rotavirus VP8 subunit parenteral vaccine candidate

Xue

Che

et al. 2015

Vaccine

Self Cite

View full text Add to dashboard Cite

Section: Differential Scanning Calorimetry (Dsc)mentioning

confidence: 99%

“…The mice with a diarrhea score of 1 and ≥2 were considered as normal and with diarrhea, respectively. And those with a diarrhea score of 3 were considered as with severe diarrhea [25].…”

Section: Animal Immunization and Virus Challengementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Characterization and protective efficacy in an animal model of a novel truncated rotavirus VP8 subunit parenteral vaccine candidate

Xue

Che

et al. 2015

Vaccine

Self Cite

View full text Add to dashboard Cite

“…VP6, as the group antigen of RV, is the major structural protein forming the middle layer in the triple-layered viral capsid. For the last few years, studies have shown that VP6 could stimulate a protective immune response (Bugli et al, 2014;Li et al, 2014;Marashi et al, 2014;Pastor et al, 2014;Shoja et al, 2015) and a short fragment of VP6 could provide significant reduction in virus infectivity in vitro (El-Senousy et al, 2013). Previous experiments demonstrated that anti-VP6 llama-derived single-chain antibody fragments (VHH) had neutralizing activity against VP6 in vitro (Garaicoechea et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity and antigenicity of a recombinant chimeric protein containing epitopes of poliovirus type 1

Xx¹,

Wang²,

Wy³

et al. 2016

View full text Add to dashboard Cite

Summary. -To design a vaccine that simultaneously prevents both rotavirus (RV) and poliovirus (PV), a PV type 1 (PV1) chimeric protein using RV VP6 as a vector (VP6F) was constructed, expressed in Escherichia coli expression system and characterized by SDS-PAGE, Western blot, immunofluorescence assay and neutralization test. The results showed that the chimeric protein reacted with anti-VP6F and anti-PV1 antibodies and elicited production of serum antibodies against the chimeric protein in guinea pigs. Antibodies against the chimeric protein neutralized RV Wa and PV1 infection in vitro. The results provided a relevant possibility of developing novel approaches in the rational design of vaccines effective against both RV and PV.Keywords: chimeric protein; neutralizing activity; rotavirus; poliovirus epitope * Corresponding author. E-mail: chenyd@imbcams.com.cn; phone: +86-871-68335402. Abbreviations: CPE = cytopathic effect; PV = poliovirus; RV = rotavirus; TCID 50 = 50% tissue culture infectivity doses

show abstract

Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology

Rodrigues

Soares

Guerreiro

et al. 2015

Biotechnology Journal

View full text Add to dashboard Cite

Vaccination is one of the most effective interventions in global health. The worldwide vaccination programs significantly reduced the number of deaths caused by infectious agents. A successful example was the eradication of smallpox in 1979 after two centuries of vaccination campaigns. Since the first variolation administrations until today, the knowledge on immunology has increased substantially. This knowledge combined with the introduction of cell culture and DNA recombinant technologies revolutionized vaccine design. This review will focus on vaccines against human viral pathogens, recent developments on vaccine design and cell substrates used for their manufacture. While the production of attenuated and inactivated vaccines requires the use of the respective permissible cell substrates, the production of recombinant antigens, virus-like particles, vectored vaccines and chimeric vaccines requires the use - and often the development - of specific cell lines. Indeed, the development of novel modern viral vaccine designs combined with, the stringent safety requirements for manufacture, and the better understanding on animal cell metabolism and physiology are increasing the awareness on the importance of cell line development and engineering areas. A new era of modern vaccinology is arriving, offering an extensive toolbox to materialize novel and creative ideas in vaccine design and its manufacture.

show abstract

Improved characteristics and protective efficacy in an animal model of E. coli-derived recombinant double-layered rotavirus virus-like particles

Cited by 35 publications

References 51 publications

Characterization and protective efficacy in an animal model of a novel truncated rotavirus VP8 subunit parenteral vaccine candidate

Characterization and protective efficacy in an animal model of a novel truncated rotavirus VP8 subunit parenteral vaccine candidate

Immunogenicity and antigenicity of a recombinant chimeric protein containing epitopes of poliovirus type 1

Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology

Contact Info

Product

Resources

About